Amyloidosis trials in Sweden

In Sweden 15 Also abroad 184

15 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Solna, Umeå
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
Phase 3Enrolling by invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Gothenburg, Solna, Umeå
Age
18 years and over
People
700 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT06679946
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Huddinge, Umeå
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Goteborg, Lund, Solna
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Stockholm, Umea
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
No phaseTaking people
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
Where
Multiple Locations
Age
18 years and over
People
2,000 worldwide
Run by
Bayer
See details and how to joinNCT07235462
No phaseTaking people
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Where
Södertälje, Umeå
People
52,121 worldwide
Run by
AstraZeneca
See details and how to joinNCT06355934
Phase 3Not yet taking people in Sweden
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Gothenburg, Lund, Skellefte, Stockholm
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
No phaseTaking people
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
Where
Gothenburg, Solna, Vasterbottens Lan
Age
18 years and over
People
500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07690436
Phase 3Not yet taking people in Sweden
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Where
Umea
Age
18 years and over
People
250 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
Umea
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 2/3Enrolling by invitation
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Where
Umea
Age
18 years and over
People
72 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT05697861 · EU 2023-507385-11-00
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Gothenburg, Skellefteå
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493
No phaseNot yet taking people in Sweden
Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis
Where
Gothenburg, Linköping, Lund, Skellefteå, Stockholm, Umeå, Uppsala
Age
18 years and over
People
34 worldwide
Run by
Region Skane
See details and how to joinNCT07413081
No phaseEnrolling by invitation
Sahlgrenska Cardiomyopathy Project
Where
Gothenburg
Age
18 years to 99 years
People
3,000
Run by
Göteborg University
See details and how to joinNCT03527342